NAX Strengthens Leadership Team With Appointment of Patrick Nicolet - Former Capgemini Group CTO
9.9.2021 15:00:00 EEST | Business Wire | Press release
New Asset eXchange (NAX), a company that creates new markets and ecosystems around corporate assets, has today announced the appointment of Patrick Nicolet as Chair of its technology platform, Bridge.
Patrick Nicolet - formerly Group CTO and Executive Board Member at Capgemini - will lead NAX’s technology platform as it works on the development and deployment of enterprise-grade solutions to power digital asset economies. The platform’s current focus areas include coin & tokenization solutions, payment & disbursement processing, aggregated blockchain solutions and deployment services.
The arrival of Patrick Nicolet coincides with the appointment of Dr. Heiner Leisten as Chair of the Genesis Project, NAX’s development platform, and Joe Euteneuer as Chair of LiQid, NAX’s securitization platform. Both already sit on the NAX Board alongside high-profile business figures such as Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank.
Jeff Schumacher, CEO and Founder, NAX said: “Patrick is a world-class technologist and business leader and brings vast experience to the team. His arrival further strengthens the NAX ecosystem; a development platform that mines corporate assets to create asset-backed ventures and markets, a technology platform that provides technology tools and solutions to power digital assets, and a securitization platform to make corporate assets tradeable. With Heiner, Patrick, and Joe at the helm of each, alongside our broader leadership team, we’re building an infrastructure that can fully realize the trillions of dollars of dormant value residing in corporate assets.”
NAX formally launched in January 2021 after two and a half years in stealth development. It focuses on building new markets and ecosystems around corporate assets. Led by serial entrepreneur Jeff Schumacher, NAX comprises three distinct but complementary platforms that provide a new lifecycle to repurpose corporate assets:
-
Creating asset backed ventures and markets
NAX’s development platform Genesis Project mines dormant corporate assets to create asset-backed ventures and markets.
-
Leveraging assets for DeFi
NAX’s technology platform Bridge deploys enterprise-grade technology solutions to power digital asset economies.
-
Making alternative assets tradeable
NAX’s trading platform LiQid securitizes corporate assets to make them tradeable.
Schumacher added: “The vast majority of assets globally are not listed. At NAX, we’re building an infrastructure to change that. From seed to securitization, we unlock value from underutilized corporate assets and, in doing so, are building next generation markets.”
About NAX
NAX enables a corporate partner to realize the full potential of its proprietary assets through the development of new asset-backed ventures and securities.
From seed to securitization, NAX co-leads the commercialization of these initiatives alongside its partners. It has three distinct but complementary platforms to repurpose corporate assets: a development platform, a technology platform and a securitization platform.
NAX maintains its headquarters in Manhattan Beach, CA and has offices in Palo Alto, New York, London, Paris, Zurich and Frankfurt.
For more information, visit http://www.naxgrp.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005501/en/
Contact information
Media contacts
Vested
Danny Calogero
nax@fullyvested.com
+447891 563 294
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom